4//SEC Filing
Daruwala Paul 4
Accession 0001209191-19-061576
CIK 0001610618other
Filed
Dec 19, 7:00 PM ET
Accepted
Dec 20, 4:39 PM ET
Size
20.4 KB
Accession
0001209191-19-061576
Insider Transaction Report
Form 4
Daruwala Paul
Chief Medical Officer
Transactions
- Award
Employee Stock Option (right to buy)
2019-12-18+32,592→ 32,592 totalExercise: $2.45Exp: 2026-12-17→ Common Stock (32,592 underlying) - Award
Employee Stock Option (right to buy)
2019-12-18+17,125→ 17,125 totalExercise: $2.45Exp: 2026-12-17→ Common Stock (17,125 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2019-12-18−50,000→ 0 totalExercise: $9.89Exp: 2026-03-15→ Common Stock (50,000 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2019-12-18−25,688→ 0 totalExercise: $6.86Exp: 2025-02-18→ Common Stock (25,688 underlying) - Award
Employee Stock Option (right to buy)
2019-12-18+33,333→ 33,333 totalExercise: $2.45Exp: 2026-12-17→ Common Stock (33,333 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2019-12-18−55,000→ 0 totalExercise: $7.80Exp: 2027-03-30→ Common Stock (55,000 underlying) - Award
Employee Stock Option (right to buy)
2019-12-18+4,074→ 4,074 totalExercise: $2.45Exp: 2026-12-17→ Common Stock (4,074 underlying)
Footnotes (8)
- [F1]The option provided for vesting in a series of 36 monthly installments and was fully vested on February 19, 2018.
- [F2]On December 18, 2019, the issuer canceled, pursuant to the issuer's option exchange program, an option for 25,688 shares of the Issuer's common stock granted to the reporting person on February 19, 2015. In exchange, the reporting person received a replacement option, for 17,125 shares, having an exercise price of $2.45 a share.
- [F3]The option shall vest in full on December 18, 2020.
- [F4]The option provided for vesting in a series of 36 monthly installments and was fully vested on March 16, 2019.
- [F5]On December 18, 2019, the issuer canceled, pursuant to the issuer's option exchange program, an option for 50,000 shares of the Issuer's common stock granted to the reporting person on March 16, 2016. In exchange, the reporting person received a replacement option, for 33,333 shares, having an exercise price of $2.45 a share.
- [F6]The option provided for vesting in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2017 such that the option would have been fully vested on March 31, 2020.
- [F7]On December 18, 2019, the issuer canceled, pursuant to the issuer's option exchange program, an option for 55,000 shares of the Issuer's common stock granted to the reporting person on March 31, 2017. In exchange, the reporting person received two replacement options, for an aggregate of 36,666 shares, having an exercise price of $2.45 a share.
- [F8]The option vests as follows: 1/3rd shall vest on December 18, 2020, and the balance of the shares will vest in twenty-four (24) equal monthly installments thereafter, such that all shares subject to the option shall be fully vested on December 18, 2022.
Documents
Issuer
Cidara Therapeutics, Inc.
CIK 0001610618
Entity typeother
Related Parties
1- filerCIK 0001639144
Filing Metadata
- Form type
- 4
- Filed
- Dec 19, 7:00 PM ET
- Accepted
- Dec 20, 4:39 PM ET
- Size
- 20.4 KB